Report Expects Drug MNCs To Favor China, India Partners
This article was originally published in PharmAsia News
Executive Summary
An international report suggests multinational drug makers prefer signing long-term manufacturing contracts with Asian counterparts, particularly in China and India. The Citigroup report said the trend would be to treat Asian companies as partners rather than suppliers or vendors of drugs. The report is based on an annual survey of pharmaceutical and biotechnology companies. The report noted China's WuXi PharmaTech and India's Nicholas Piramal appear to be the most likely companies sought out for those partnerships. Close behind, it named Dishman Pharmaceuticals & Chemicals and Jubilant Organosys, both of India. (Click here for more